CATO · CNAS + ANAB ISO 17034 accredited reference material producer
销售顾问Sales contact Kaka Lu+86 185 2048 1969kaka@cato-chem.com
技术文库Knowledge Base

技术文库Knowledge Base

围绕药物杂质、药物研究、注册申报、杂质分析、药物合成五个方向,整理法规解读、检测方法、品种杂质谱、药典差异、对照品实务与发补实务等原创技术内容,含具体品种的杂质覆盖度统计与目录数据,供研发、QC 与注册人员检索参考。

Original technical writing across five areas: pharmaceutical impurities, drug research, regulatory filing, impurity analysis and drug synthesis. Covers regulatory interpretation, analytical methods, drug-substance impurity profiles, pharmacopoeial differences, reference standard practice and deficiency-response practice, with impurity coverage statistics and catalogue data for individual substances, for R&D, QC and regulatory affairs professionals.

法规解读Regulatory Insight

法规解读Regulatory Insight
Gadobutrol Has an Impurity That Is Also an Excipient, and a Metal That Q3D Does Not Cover
EP impurity B is the free ligand of gadobutrol and calcobutrol sodium is the same ligand added as an excipient; with gadolinium outside the 24 Q3D elements, speciation rather than mass drives the fileEP impurity B is the free ligand of gadobutrol and calcobutrol sodium is the same ligand added as an excipient; with gadolinium outside the 24 Q3D…
2026-11-17
法规解读Regulatory Insight
Oxaliplatin's Impurity File Is a Ligand-Exchange Sequence, and Platinum Is the Element Q3D Cannot Assess
Five lettered oxaliplatin impurities map to five coordination events, and the label's chloride ban explains the dichloro species that is also the active drugFive lettered oxaliplatin impurities map to five coordination events, and the label's chloride ban explains the dichloro species that is also the…
2026-11-16
法规解读Regulatory Insight
Aripiprazole: Two Fragments, One Active Metabolite and a Nitrosamine That Is Not on the Drug
Most aripiprazole impurities are fragments or monochloro analogues, not modified drugs. Why EP E is a metabolite, and why the nitrosamine sits on EP impurity B.Most aripiprazole impurities are fragments or monochloro analogues, not modified drugs. Why EP E is a metabolite, and why the nitrosamine sits on EP…
2026-11-14
法规解读Regulatory Insight
Cinacalcet: The Secondary Amine Is the Drug, and the Nitrosamine Limit Is 8 ppm
Cinacalcet's N-H is the pharmacophore, so nitrosamine risk cannot be engineered out. At 180 mg a day the 1.5 microgram threshold becomes 8.3 ppm.
2026-11-13
法规解读Regulatory Insight
Metronidazole at 2.25 Grams a Day: Where the 0.10 Per Cent Impurity Limit Quietly Stops Applying
Metronidazole carries a gram-sized dose, two nitration positions and isobaric analogues, so the absolute cap in ICH Q3A binds before the percentage doesMetronidazole carries a gram-sized dose, two nitration positions and isobaric analogues, so the absolute cap in ICH Q3A binds before the percentage…
2026-11-12
法规解读Regulatory Insight
The Nitrosamine in Sildenafil Citrate Sits One Methyl Group Away From the Drug
Sildenafil has no secondary amine, so the drug cannot be nitrosated. Its desmethyl degradant can, and the resulting limit is 1 ppm against a 500 ppm reporting threshold.Sildenafil has no secondary amine, so the drug cannot be nitrosated. Its desmethyl degradant can, and the resulting limit is 1 ppm against a 500 ppm…
2026-11-10
法规解读Regulatory Insight
Fluoxetine: The N-Methyl That Carries Both the Pharmacology and the Nitroso Group
N-nitroso-fluoxetine exceeded 100 ng per day in a marketed product and forced a temporary withdrawal. The same N-methyl is what makes the drug selective.N-nitroso-fluoxetine exceeded 100 ng per day in a marketed product and forced a temporary withdrawal. The same N-methyl is what makes the drug…
2026-11-09
法规解读Regulatory Insight
Allopurinol: Hydrazine Cannot Be Designed Out, So Five ppm Becomes the Number
Every route to the pyrazolo-pyrimidine ring starts with hydrazine. At 300 mg a day the M7 limit works out to 5 ppm, and the release method cannot see it.Every route to the pyrazolo-pyrimidine ring starts with hydrazine. At 300 mg a day the M7 limit works out to 5 ppm, and the release method cannot see…
2026-11-06
法规解读Regulatory Insight
Caspofungin Acetate: The Impurities That Q3C and Q3D Have No Table For
Three semi-synthetic steps bring a thiol, a borane and a diamine into the caspofungin process. None is a Q3C solvent and none is a Q3D element, so the residue work has to be argued rather than tabulated.Three semi-synthetic steps bring a thiol, a borane and a diamine into the caspofungin process. None is a Q3C solvent and none is a Q3D element, so…
2026-11-05
法规解读Regulatory Insight
Doxycycline Hyclate: A Two-by-Two Epimer Grid That the Assay Cannot See
Removing the 6-hydroxyl turned a dehydration problem into an epimerization problem. Four epimers share one formula, and a stability programme built on assay and total impurities will miss all of them.Removing the 6-hydroxyl turned a dehydration problem into an epimerization problem. Four epimers share one formula, and a stability programme built…
2026-11-04
法规解读Regulatory Insight
氯沙坦钾的元素杂质与残留溶剂:四氮唑环合把锡、钯和叠氮一起带进了路线Elemental Impurities and Residual Solvents in Losartan Potassium: How the Tetrazole Cyclisation Brings Tin, Palladium and Azide Into the Route
沙坦类的元素杂质风险,不在最后一步成盐,而在联苯四氮唑那个环怎么合起来。钯来自联苯偶联,锡来自有机锡叠氮路线,叠氮根本身既不是 Q3D 的元素也不是 Q3C 的溶剂——它落在两套框架之外,却恰恰是这类品种被监管盯上的起点。Losartan potassium carries no metal of its own; the metals arrive with the tetrazole ring closure. This article maps each unit operation of the route…
2026-11-03
法规解读Regulatory Insight
甲氨蝶呤的亚硝胺不在脂肪胺上:蝶啶环外那个弱碱氮,为什么反而最容易被亚硝化Methotrexate's Nitrosamine Is Not on an Aliphatic Amine: Why the Weakly Basic Nitrogen Outside the Pteridine Ring Is Nitrosated First
甲氨蝶呤的 N-亚硝基杂质(EP 杂质 L)形成在一个反常的位置——蝶啶环外、碱性极弱的芳香仲胺。本文从亚硝化机理、剂量与限度的换算关系、方法学陷阱与申报发补四个角度,讲清这个 NDSRI 的真实风险边界。The N-nitroso impurity of methotrexate (EP Impurity L) forms at an anomalous site: an aromatic secondary amine outside the pteridine ring with very…
2026-11-02
法规解读Regulatory Insight
异烟肼的致突变杂质不用外找:酰肼键一断就是肼,而它见到醛基就成腙Isoniazid's Mutagenic Impurity Needs No Outside Source: Cleave the Hydrazide and You Have Hydrazine, Which Forms a Hydrazone on Contact With Aldehydes
大多数品种的基因毒性杂质是从外面带进来的,异烟肼不是。它的致突变杂质就是自己水解出来的肼,工艺上还用水合肼做原料,两条路殊途同归。更要命的是折算:300 mg 的日剂量把 TTC 压到 5 ppm 量级,而 0.05% 的报告阈值在同一剂量下等于 150 μg/天,相差一百倍。Most genotoxic impurities are brought in from outside; isoniazid's is not. Its mutagenic impurity is the hydrazine released by its own hydrolysis…
2026-10-31
法规解读Regulatory Insight
环孢素的杂质限度为什么不能套 0.10%:一支发酵环肽的三层限度Why Ciclosporin's Impurity Limits Cannot Copy 0.10%: Three Tiers for a Fermentation Cyclopeptide
把 ICH Q3A 的 0.10% 直接写进环孢素的质量标准,是做发酵类多肽最容易踩的坑。这个品种的杂质绝大多数不是降解出来的,而是菌种一并发酵出来的同系物;它们该被逐个指定、单独定限,而不是塞进一个统一的百分比里。而 210 nm 的检测波长,又给这套限度加了一层定量不确定性。Writing ICH Q3A's 0.10% straight into a ciclosporin specification is the easiest mistake in fermentation peptides. Most of its impurities are…
2026-10-30
法规解读Regulatory Insight
碘克沙醇的卤代丙醇类基因毒性杂质:65 克一次的注射剂,TTC 折下来只剩 0.02 ppmHalopropanol Genotoxic Impurities in Iodixanol: A 65-Gram Injection Where the TTC Converts to Just 0.02 ppm
碘克沙醇的三碳桥来自卤代丙醇类烷基化试剂,环氧氯丙烷、3-氯-1,2-丙二醇、1,3-二氯-2-丙醇都因此进入风险清单。这三个物种无紫外吸收,常规有关物质方法一个也看不见;而一次 100 mL 的检查用量把 TTC 折算限压到 0.02 ppm 量级,成品检验根本承担不了。本文给出按元素差拆解 13 条目录条目的方法、剂量折算表与清除率论证路径。Iodixanol's three-carbon bridge comes from halopropanol alkylating reagents, putting epichlorohydrin, 3-chloro-1,2-propanediol and…
2026-10-25
法规解读Regulatory Insight
阿奇霉素的亚硝胺:两个叔胺氮、三种可能物种,为什么它是大环内酯里的特例Azithromycin's Nitrosamine: Two Tertiary Amine Nitrogens, Three Possible Species, and Why It Is the Macrolide Exception
阿奇霉素有两个叔胺氮——环内一个 N-甲基,去氧糖胺 3′ 位一个二甲氨基。叔胺不能直接亚硝化,必须先脱掉一个甲基再上亚硝基,于是两个位点各走一遍就是两种单亚硝基物,都走一遍就是双亚硝基物。加拿大卫生部的 NDSRI 汇总表把这两个结构分别列入阿奇霉素项下。本文拆位点化学、三种物种的推导、500 mg 与 1 g 两个方案下 3 ppm 与 1.5 ppm 的差别,以及为什么克拉霉素那套方案不能照搬。Azithromycin has two tertiary amine nitrogens, one N-methyl in the ring and one dimethylamino on the desosamine. Tertiary amines cannot be nitrosated…
2026-10-24
法规解读Regulatory Insight
对乙酰氨基酚的 4-氨基苯酚:原料药 50 ppm、制剂 1000 ppm,这 20 倍不是笔误4-Aminophenol in Acetaminophen: 50 ppm for the Drug Substance and 1000 ppm for the Product, and the 20-Fold Gap Is Not a Typo
同一个杂质、同一个患者,原料药端限 50 ppm、制剂端限 1000 ppm。这 20 倍不是笔误,而是一条「带入量控制 + 货架期增量预算」的双轨结构。本文拆解三件事:4-氨基苯酚的工艺残留与水解降解两个来源、50 ppm 这一档为什么长期靠比色法而 0.1% 可以交给 HPLC、以及把 0.1% 换算成 4 mg/日后为什么会和 ICH M7 的 TTC 差出三个数量级。附中国药典四个剂型三个波长的取舍。One impurity, one patient, yet 50 ppm at the drug substance stage and 1000 ppm at the product stage. The twenty-fold difference is a two-track…
2026-10-23
法规解读Regulatory Insight
甲磺酸奥希替尼的基因毒性杂质:丙烯酰胺是药效团,真正的风险在另外两条支路Genotoxic Impurities in Osimertinib Mesylate: Acrylamide Is the Pharmacophore, and the Real Risk Sits on Two Other Branches
奥希替尼分子里的丙烯酰胺本身就是 ICH M7 的警示结构,但它是药效团而不是杂质。真正要盯的是:两个叔胺经去甲基、去侧链后生成的仲胺如何亚硝化,甲磺酸盐在醇类溶剂里如何生成烷基磺酸酯,以及丙烯酰胺作为亲电体产生的二聚体与加合物。本文用结构推导、目录实证条目与剂量换算把三条支路分开讲,并给出方法矩阵与发补要点。The acrylamide in osimertinib is itself an ICH M7 structural alert, but it is the pharmacophore rather than an impurity. The real targets are how the…
2026-10-22
法规解读Regulatory Insight
富马酸伏诺拉生的稳定性研究:一个在酸里不降解的 P-CAB,强降解该怎么做Stability Study Design for Vonoprazan Fumarate: An Acid-Stable P-CAB Where Conventional Acid Stress Tells You Nothing
富马酸伏诺拉生是设计成耐酸的 P-CAB,常规酸档强降解对它的信息量接近于零。本文从分子结构出发指出真正的四个风险位点(仲胺亚硝化、苄位氧化、吡啶磺酰基光解、富马酸盐水分),给出把亚硝化做成独立降解通道的试验设计、ICH Q1A/Q1B 条件对照表,以及 20 mg/天下 0.15%、75 ppm、4.8 ppm 三套限度的换算关系。Vonoprazan fumarate was designed as an acid-resistant P-CAB, so conventional acid stress yields almost no information. Working from the structure…
2026-10-20
法规解读Regulatory Insight
替格瑞洛的杂质限度:同一张标准里,0.15% 和 8 ppm 是怎么共存的Ticagrelor's Impurity Limits: How 0.15% and 8 ppm Coexist in One Specification
替格瑞洛日剂量 180 mg、六个手性中心、一个丙硫基,这三个特征决定了它的杂质限度不能用一把尺子:一般有机杂质按百分比,立体异构体单列,致突变杂质折算到 ppm 级。本文把三类尺度的换算过程摊开算一遍,并给出强制降解 9 个产物、工艺杂质 5 个、基因毒性杂质 4,6-二氯-5-硝基-2-丙硫基嘧啶的具体落点。A 180 mg daily dose, six stereocentres and a propylthio group mean ticagrelor's impurity limits cannot use one yardstick: ordinary organic impurities…
2026-10-19
法规解读Regulatory Insight
甲苯磺酸艾多沙班的潜在基因毒性杂质:风险不在主成分上,在那个「反离子」上Potential Genotoxic Impurities in Edoxaban Tosylate: The Risk Sits on the Counterion, Not the Drug Substance
甲苯磺酸艾多沙班是对甲苯磺酸盐。它的问题不来自主成分降解,而来自反离子——磺酸与工艺溶剂里的低碳醇在强酸升温条件下有机会生成烷基磺酸酯,这是一类公认的烷基化剂。本文讲清生成条件、TTC 怎么折算成浓度限、以及工艺上到底该控哪几个参数。Edoxaban tosylate's problem does not come from degradation of the parent but from the counterion: sulfonic acids and lower alcohols present in…
2026-10-18
法规解读Regulatory Insight
氨氯地平的亚硝胺杂质:二氢吡啶环上那个「不像仲胺的仲胺」Nitrosamine Impurities in Amlodipine: The Secondary Amine That Does Not Look Like One on the Dihydropyridine Ring
氨氯地平的风险评估最常见一句结论是「分子里没有仲胺」。它错在第一步:1,4-二氢吡啶环的 N1-H 就是仲胺,只是共轭后碱性弱到几乎不像胺。本文拆解这个位点为什么会被漏掉、亚硝化剂在二氢吡啶上的两条竞争路径、12 条 N-亚硝基条目说明了什么、限度怎么从 TTC 落到 ppm,以及制剂端真正起作用的三个参数。The most common conclusion in amlodipine risk assessments is that the molecule contains no secondary amine. That is wrong at the first step: the N1-H…
2026-10-17
法规解读Regulatory Insight
达格列净的元素杂质与残留溶剂:C-芳基葡萄糖苷这条路线,金属和溶剂是从哪儿进来的Elemental Impurities and Residual Solvents in Dapagliflozin: Where Metals and Solvents Enter the C-Aryl Glucoside Route
从达格列净的 C-芳基葡萄糖苷骨架与 (S)-丙二醇溶剂化物形态出发,逐条映射这套合成单元操作可能带入的元素与溶剂,给出 ICH Q3D 口服 PDE 与 Q3C 溶剂分类的落地方式,以及无药典专论时元素杂质与残留溶剂的申报路径与常见发补追问。Starting from the C-aryl glucoside skeleton and the (S)-propylene glycol solvate form, this article maps the elements and solvents each unit…
2026-10-16
法规解读Regulatory Insight
盐酸二甲双胍中的 NDMA:原料药检不出、缓释片却超标,问题出在哪一环NDMA in Metformin Hydrochloride: Undetectable in the Drug Substance Yet Over Limit in the Extended-Release Tablet
二甲双胍分子自带两个 N,N-二甲基,日剂量又高达克级。本文讲清它的亚硝胺风险从哪来、高日剂量怎样把浓度限度压到 ppb 级、检测为什么容易被干扰,以及限度计算与申报的落地口径。Metformin carries two N,N-dimethyl groups and is dosed in grams. This article covers where the nitrosamine risk originates, how the high daily dose…
2026-10-14
法规解读Regulatory Insight
利伐沙班的亚硝胺杂质:母体里那个氮是酰胺氮,风险其实藏在带氨基的杂质里Nitrosamine Impurities in Rivaroxaban: The Parent Nitrogen Is an Amide, and the Risk Hides in Amino-Bearing Impurities
利伐沙班分子里没有游离仲胺,它的亚硝胺风险不来自原料药本身,而来自工艺中带氨基的中间体与杂质。本文从结构推导风险落点,并给出目录中 5 个 N-亚硝基条目背后的化学逻辑与监管框架。Rivaroxaban has no free secondary amine, so its nitrosamine risk does not come from the drug substance but from amino-bearing intermediates and…
2026-10-13
法规解读Regulatory Insight
亚硝胺杂质控制全解读:从致突变杂质框架到 NDSRI,原料药与制剂企业怎么做Nitrosamine Impurity Control in Full: From the Mutagenic Impurity Framework to NDSRIs, and What Drug Substance and Product Manufacturers Must Do
系统梳理亚硝胺杂质的监管背景、法规框架、形成机理、风险评估与控制策略、检测方法要点,以及 NDSRI 的新挑战,附常见问题与对照品选用建议。A systematic treatment of the regulatory background, legal framework, formation mechanisms, risk assessment and control strategy for nitrosamines…
2026-10-10

检测方法Analytical Methods

检测方法Analytical Methods
Budesonide Is Two Epimers and One Acetal: Why the Ratio, Not the Peak Count, Is the Specification
USP holds the C-22S epimer at 40.0 to 51.0 per cent of the pair, acid opens the acetal to EP impurity A, and the HBr step that corrects the ratio leaves brominated steroids behindUSP holds the C-22S epimer at 40.0 to 51.0 per cent of the pair, acid opens the acetal to EP impurity A, and the HBr step that corrects the ratio…
2026-11-17
检测方法Analytical Methods
Thioctic Acid Fails Two Ways: Light Gives the Reduced Thiol, Heat Above 58 °C Gives a Polymer With No Peak
A strained 1,2-dithiolane makes thioctic acid polymerise, not hydrolyse; light and heat give different products and the 332 nm assay sees both as one lossA strained 1,2-dithiolane makes thioctic acid polymerise, not hydrolyse; light and heat give different products and the 332 nm assay sees both as one…
2026-11-16
检测方法Analytical Methods
Clarithromycin Dissolves Best in the Medium That Destroys It
Clarithromycin is soluble and unstable in the same acid. How the C6 methyl reroutes degradation to cladinose loss, and what that does to dissolution testing.Clarithromycin is soluble and unstable in the same acid. How the C6 methyl reroutes degradation to cladinose loss, and what that does to dissolution…
2026-11-14
检测方法Analytical Methods
Sofosbuvir: Seven Entries Share One Formula, and the Spectra Cannot Tell Them Apart
Seven catalogued sofosbuvir entries carry C22H29FN3O9P: a phosphorus epimer, a D-alanine analogue and a 3-prime regioisomer hide behind one nominal mass.Seven catalogued sofosbuvir entries carry C22H29FN3O9P: a phosphorus epimer, a D-alanine analogue and a 3-prime regioisomer hide behind one nominal…
2026-11-13
检测方法Analytical Methods
Irinotecan Hydrochloride: The Lactone Ring Is Not an Impurity, and the Assay Cannot Tell You It Opened
Irinotecan is formulated at pH 3.5 because its E-ring lactone opens to an inactive acid, a change no low-pH related-substances method can see
2026-11-12
检测方法Analytical Methods
Folic Acid: A Photolysis That Accelerates and Products That Leave the Window Before the Parent
Folic acid photolysis cleaves C9-N10 into two polar fragments, then speeds up as its own products sensitise the reaction. Both leave the window early.
2026-11-11
检测方法Analytical Methods
Iopamidol: One Lactate Stereocenter, Three Isobars, and a Formula That Proves Nothing
Iopamidol is the only non-ionic contrast agent built on a lactate. That one stereocenter drives its impurity map, and three other entries share its formula exactly.Iopamidol is the only non-ionic contrast agent built on a lactate. That one stereocenter drives its impurity map, and three other entries share its…
2026-11-11
检测方法Analytical Methods
Four Substances, One Formula: Why Latanoprost Eye Drops Fail on Content, Not on Impurity Limits
At 1.5 micrograms a day the ICH Q3B identification threshold for latanoprost is 1.0 percent. Four entries share C26H40O5, and only chromatography separates them.At 1.5 micrograms a day the ICH Q3B identification threshold for latanoprost is 1.0 percent. Four entries share C26H40O5, and only chromatography…
2026-11-10
检测方法Analytical Methods
Ibuprofen: In a Racemate the Enantiomer Is the Drug, So What Is the Chiral Test For?
Four impurities share one molecular formula, and the enantiomer is not one of them. What the ibuprofen panel can and cannot tell you, and where the logic breaks at dexibuprofen.Four impurities share one molecular formula, and the enantiomer is not one of them. What the ibuprofen panel can and cannot tell you, and where the…
2026-11-06
检测方法Analytical Methods
Hydrochlorothiazide: One Methylene Carbon Explains the Whole Impurity Profile
The same carbon can leave as formaldehyde, stay as a bridge between two molecules, or be lost as hydrogen. Four impurities, one atom, and an assay that sees none of them.The same carbon can leave as formaldehyde, stay as a bridge between two molecules, or be lost as hydrogen. Four impurities, one atom, and an assay…
2026-11-05
检测方法Analytical Methods
Nicotinamide: Three Compounds With One Formula, and the Nitrile That Never Hydrolyzed
Nicotinamide, picolinamide and isonicotinamide share C6H6N2O. With 3-cyanopyridine on one side and nicotinic acid on the other, the profile is a selectivity map.Nicotinamide, picolinamide and isonicotinamide share C6H6N2O. With 3-cyanopyridine on one side and nicotinic acid on the other, the profile is a…
2026-11-04
检测方法Analytical Methods
硝苯地平的光稳定性:同一个邻硝基,把光解拆成了三条路Photostability of Nifedipine: One Ortho-Nitro Group Splits Photolysis Into Three Pathways
通常的说法是二氢吡啶见光变成吡啶,但在硝苯地平上这一步只是开头。邻硝基被激发后会先还原成亚硝基,再经光化学缩合长出氧化偶氮、N,N'-二氧化物和内酰胺——室内光下放 30 天,研碎的片剂里能同时出现六个组分。这也决定了 ICH Q1B 的两个光照选项,在这个品种上并不等价。The usual account has a dihydropyridine become a pyridine on exposure to light, but in nifedipine that is only the opening step. The excited…
2026-11-03
检测方法Analytical Methods
华法林钠的晶体里锁着 8.3% 的异丙醇:一道 68% RH 的坎,和一批溶出掉了 23% 的片Warfarin Sodium Locks 8.3% Isopropanol Inside Its Crystal: A 68% RH Threshold and a Batch That Lost 23% of Its Dissolution
华法林钠被当成多晶型品种管了很多年,但它其实没有普通意义上的多晶型:市售结晶品是异丙醇溶剂化物,按重量含 8.3% 溶剂。这个数字被当成杂质去卡,整条链路都会错;而让片子出问题的也不是晶型互变,是它在湿气里歧化成难溶的游离酸。Warfarin sodium has been managed as a polymorphic substance for years, yet the commercial crystalline material is an isopropanol solvate containing…
2026-10-31
检测方法Analytical Methods
泊沙康唑在碱里几乎不降解:一个让强制降解试验白做的品种Posaconazole Barely Degrades in Base: The Substance That Makes an Entire Forced Degradation Condition Redundant
泊沙康唑的强制降解报告里,碱档常常是一片干净的基线。很多人把它读成「方法专属性通过」,其实那是一次空转——这个品种在碱性条件下本来就稳。真正的难点在另一头:本目录里 15 条条目与母体同分子式,一级质谱分不出谁是谁,方法必须靠对照品一条条钉住。In posaconazole forced degradation reports the base condition often shows a clean baseline. Many read that as proof of specificity, when it is an…
2026-10-30
检测方法Analytical Methods
伊曲康唑的一个主峰里有四个分子:顺式二氧戊环带来的手性债Four Molecules Inside One Itraconazole Main Peak: The Chiral Debt of the cis-Dioxolane
伊曲康唑的理论立体异构体有八个,药用的是顺式二氧戊环那一组四个,构成两对对映体。对映体在非手性柱上共洗脱,所以常规反相方法最多给你两个峰。这篇文章从三个手性中心的来源讲到两步手性拆分的实操,再讲申报时「立体异构体组成一致性」该怎么写。Itraconazole has eight theoretical stereoisomers, of which the cis-dioxolane set of four is used medicinally, forming two enantiomeric pairs. The…
2026-10-29
检测方法Analytical Methods
奥氮平的氧化不在哌嗪上:被打开的是那个含硫的五元环Olanzapine's Oxidation Is Not on the Piperazine: What Opens Is the Sulfur-Containing Five-Membered Ring
奥氮平的两个主要氧化降解物都已由核磁与单晶确证,结构指向同一个位点——噻吩环的开环,而不是多数人以为的哌嗪氮氧化。产物骨架从噻吩并苯并二氮杂䓬变成了苯并二氮杂䓬。这决定了强制降解怎么设计、辅料怎么筛、250 nm 下那八个峰怎么分开。Both major oxidative degradants of olanzapine have been confirmed by NMR and single-crystal work, and both point to the same site: opening of the…
2026-10-29
检测方法Analytical Methods
美罗培南的聚合杂质:β-内酰胺开环只是第一步,二聚体的位置异构才是难点Polymeric Impurities in Meropenem: β-Lactam Ring Opening Is Only the First Step, and the Dimer Regioisomers Are the Real Difficulty
碳青霉烯的降解从来不是「开环就完了」。美罗培南侧链上的吡咯烷带着一个游离仲胺,它会在溶液里去找另一个分子的 β-内酰胺,生成一系列分子量成倍、结构互为位置异构的聚合杂质。这类杂质在反相柱上分不开、在 SEC 上又只能看到一个鼓包,而它恰恰是被动皮肤过敏反应的怀疑对象。Carbapenem degradation never stops at ring opening. The pyrrolidine on meropenem's side chain carries a free secondary amine that seeks another…
2026-10-28
检测方法Analytical Methods
伏立康唑的立体异构体:酸里长出来的为什么是 C2 差向体,而不是对映体Voriconazole's Stereoisomers: Why Acid Grows the C2 Epimer Rather Than the Enantiomer
伏立康唑的 C2 与 C3 是两个相邻手性中心,理论上存在四个立体异构体。但它们的来源完全不同:对映体只能来自拆分残留与手性起始物料,C2 差向体却会在酸性条件下自己长回来——因为 C2 是苄位叔醇。把这个差别讲清楚,才能决定哪一支进起始物料标准、哪一支进成品放行与稳定性,以及为什么反相方法和手性方法是两套不能互相替代的活。C2 and C3 of voriconazole are adjacent stereocentres, so four stereoisomers exist in theory. Their origins differ completely: the enantiomer can only…
2026-10-27
检测方法Analytical Methods
达格列净的有关物质方法:一个没有药典的品种,方法要从三处空白开始搭Related Substances in Dapagliflozin: Building a Method From Three Blanks for a Substance With No Monograph
达格列净没有药典各论可抄,检测波长只能压到苯环吸收区,API 本身还有游离体、丙二醇溶剂化物、一水合物、脯氨酸共晶多种形态。这三件事叠在一起,决定了它的有关物质方法不能照搬同类 SGLT2 抑制剂。本文按空白、形态、降解三条线拆开讲,并指出过氧化物类杂质为什么不能当常规对照品用。Dapagliflozin has no pharmacopoeial monograph to copy, detection wavelength is forced into the benzene absorption region, and the API itself exists…
2026-10-26
检测方法Analytical Methods
孟鲁司特钠的亚砜杂质:一个氧化产物,为什么在非手性柱上要出两个峰The Sulfoxide Impurity of Montelukast Sodium: Why One Oxidation Product Gives Two Peaks on an Achiral Column
孟鲁司特钠的亚砜不是普通降解物:硫醚被氧化后硫原子变成手性中心,与分子原有的 (1R) 中心组合出两个非对映异构体。20 个市售产品、11 家企业的实测数据显示它是最容易超界定限的那一个;而毒理评价又给出了非致突变的结论。这两件事放在一起,决定了它该怎么控、怎么积分、怎么在申报里说清楚。The sulfoxide of montelukast sodium is no ordinary degradant: oxidising the thioether makes sulfur a stereocentre, which combines with the existing…
2026-10-26
检测方法Analytical Methods
利托那韦的晶型 I 与晶型 II:为什么更稳定的那一相,把胶囊逼成了片剂Ritonavir Forms I and II: Why the More Stable Phase Forced the Capsule to Become a Tablet
1998 年利托那韦的问题不是纯度,而是晶型 I 在半固体胶囊的醇水环境里转成了晶型 II——更稳定、但更难溶。这件事把「晶型必须作为质量属性管理」写进了行业共识。本文拆解它的因果链、晶型定量方法的验收口径、固体分散体时代换名字继续存在的同一风险,以及 52 条有关物质里四条与母体同分子式的异构体怎么定位。The 1998 ritonavir problem was not purity but the conversion of Form I to Form II in the alcohol-water environment of a semi-solid capsule, the more…
2026-10-25
检测方法Analytical Methods
卡马西平的晶型:Form III 室温最稳,为什么湿法制粒后还是变成了二水合物Carbamazepine Polymorphs: Form III Is the Most Stable at Room Temperature, So Why Does Wet Granulation Still Convert It to the Dihydrate?
卡马西平有 4 个无水多晶型、1 个二水合物,市售是 Form III。它室温最稳定、熔点却比 Form I 低,转晶温度的文献值又能从 71 ℃ 差到 120 ℃ 以上。这篇文章不讲多晶型定义,只拆三件事:Form III 与 Form I 的互变对怎么读、水为什么比温度更危险、以及湿法制粒—干燥—包衣这条链上每一步的转晶风险和验证动作。附五种表征手段的分工表与四个常见误判。Carbamazepine has four anhydrous polymorphs and one dihydrate, and the commercial form is Form III. It is the most stable at room temperature yet…
2026-10-24
检测方法Analytical Methods
左乙拉西坦的对映体控制:一个只有酰胺、没有发色团的药,手性方法该怎么搭Enantiomeric Control of Levetiracetam: Building a Chiral Method for a Drug With Nothing but an Amide and No Chromophore
左乙拉西坦是单一对映体,分子里没有芳环、没有共轭体系,紫外检测到 210 nm 以下几乎只剩末端吸收,这把手性方法逼进「手性柱+非紫外检测器」的组合。本文从它的合成路线讲清 (R)-对映体从哪来(噁唑酮消旋与拆分残留),再给出检测器取舍、添加剂与检测器的矛盾、3000 mg/天 日剂量下的限度算法,以及 EP 杂质字母与实际结构对不上的对照品陷阱。Levetiracetam is a single enantiomer with no aromatic ring and no conjugated system, so UV below 210 nm sees little beyond end absorption, forcing…
2026-10-22
检测方法Analytical Methods
硫酸氢氯吡格雷的手性纯度:为什么溶液放几天,对映体就能长出来Chiral Purity of Clopidogrel Bisulfate: Why the Enantiomer Grows Out of Solution Within Days
氯吡格雷只有一个手性中心,但这个苄位酯碳在碱性条件下能烯醇化消旋。公开研究给出 37 °C 磷酸盐缓冲液中的消旋半衰期是 7–12 天,随 pH 变化;而 (S)-羧酸代谢物 45 天构型稳定。本文讲清对映体的两个来源、手性方法怎么搭(为什么系统适用性必须用消旋体)、限度与稳定性考察项怎么设,以及哪些品种的手性经验不能套用到这个分子上。Clopidogrel has a single stereocentre, but that benzylic ester carbon enolises and racemises under basic conditions. Published work reports a…
2026-10-21
检测方法Analytical Methods
甲磺酸伊马替尼的 α 与 β 晶型:熔点更高的那个,为什么反而是亚稳的Imatinib Mesylate Forms α and β: Why the Higher-Melting Form Is the Metastable One
甲磺酸伊马替尼的 α 与 β 是一对构象多晶型:α 的熔融峰比 β 高约 6 °C,室温下却是 β 更稳定。本文用公开的 DSC、拉曼、转晶动力学与辅料相容性数据,讲清熔点判稳定性为什么出错、反应结晶与溶剂介导转变分别给出哪种晶型、片剂端 α 如何部分转成 β、硬脂酸镁如何让两种晶型一起脱盐,以及 ICH Q6A 决策树下晶型鉴别、混晶定量与批间一致性怎么落进申报资料。Forms α and β of imatinib mesylate are a conformational polymorph pair: α melts about 6 °C higher than β yet β is the more stable at room…
2026-10-21
检测方法Analytical Methods
缬沙坦片的溶出:pH 1.2 的介质为什么什么也区分不出来Valsartan Tablet Dissolution: Why the pH 1.2 Medium Distinguishes Nothing
缬沙坦是游离酸、BCS II 类,pH 1.2 下饱和溶解度只有 0.07 mg/mL、pH 6.8 下是 5.75 mg/mL,相差八十倍。本文用这组公开数据算清 pH 1.2 介质的溶解度天花板,说明为什么该用 pH 6.8 建方法、为什么这个介质下不需要表面活性剂,并给出区分力验证、f2 使用边界、多规格豁免条件与发补三问的应对。Valsartan is a free acid and BCS Class II: saturation solubility is only 0.07 mg/mL at pH 1.2 versus 5.75 mg/mL at pH 6.8, an eighty-fold difference…
2026-10-21
检测方法Analytical Methods
艾司奥美拉唑钠的制剂处方:这个分子一到胃里就自毁,那三层包衣到底各在管什么Formulation of Esomeprazole Sodium: The Molecule Self-Destructs in the Stomach, So What Does Each of the Three Coating Layers Do?
艾司奥美拉唑是酸不稳定的前药——它的作用机制就是靠酸活化。这决定了它的口服制剂只能做成肠溶微丸,也决定了隔离层、肠溶层、增塑剂与抗粘剂各自承担什么任务。本文从结构、辅料、稳定性数据与申报口径四个层面拆开讲。Esomeprazole is an acid-labile prodrug whose mechanism depends on acid activation, which forces the oral product into enteric-coated pellets and…
2026-10-18
检测方法Analytical Methods
枸橼酸托法替布的工艺杂质:手性哌啶、双取代二聚体与氰乙酰侧链的三个入口Process Impurities in Tofacitinib Citrate: Three Entry Points, From Chiral Piperidine to Disubstituted Dimer and Cyanoacetyl Side Chain
托法替布的工艺杂质不是「一堆编号」,而是从三个位置进来的:手性哌啶起始物料的四个构型、嘧啶 4-位的双取代反应、以及氰乙酰化不完全留下的仲胺。本文按路线拆解这三类杂质的来源、为什么目录里的「单体」条目必须和二聚体一起买、以及怎么用强制降解把工艺杂质与降解产物分开。Tofacitinib's process impurities are not a pile of numbers but three entry points: the four configurations of the chiral piperidine starting…
2026-10-17
检测方法Analytical Methods
盐酸莫西沙星的立体异构体杂质:同一个分子四种构型,手性纯度到底该怎么守Stereoisomeric Impurities of Moxifloxacin Hydrochloride: Four Configurations of One Molecule, and How to Hold Chiral Purity
从莫西沙星吡咯并吡啶双环上的两个手性中心讲起,拆解四种构型的来源、非对映体与对映体在分析上的不同待遇、手性分离三条技术路线的取舍,以及 ICH Q6A 手性决策树在申报与发补中的落点。Starting from the two stereocentres on moxifloxacin's pyrrolopyridine bicycle, this article covers the origin of the four configurations, the…
2026-10-16
检测方法Analytical Methods
阿托伐他汀钙的降解杂质谱:3,5-二羟基庚酸侧链,为什么会自己关成内酯环The Degradation Profile of Atorvastatin Calcium: Why the 3,5-Dihydroxyheptanoic Acid Side Chain Closes Into a Lactone
阿托伐他汀钙的降解主线绕不开 3,5-二羟基庚酸侧链。本文从结构出发,讲清内酯化的可逆平衡、侧链氧化与光照脱氢的归属边界,以及强制降解、方法验证与放行标准的落地逻辑。Atorvastatin calcium's main degradation line runs through the 3,5-dihydroxyheptanoic acid side chain. From the structure, this article covers the…
2026-10-14
检测方法Analytical Methods
磷酸西格列汀的立体异构体杂质:全分子只有一个手性中心,手性方法为什么躲不掉Stereoisomeric Impurities of Sitagliptin Phosphate: One Stereocentre in the Whole Molecule, and Why the Chiral Method Is Unavoidable
磷酸西格列汀只有一个手性中心,看似手性控制最简单。但正因为只有这一个,对映体只能在手性色谱上现形,无处旁证。本文讲清它的手性杂质来源、手性方法开发与验证的判断逻辑,以及欧洲专论与国内申报的差别。Sitagliptin phosphate has a single stereocentre, which looks like the simplest case for chiral control. Precisely because there is only one, the…
2026-10-14
检测方法Analytical Methods
替格瑞洛的降解杂质谱:环戊二醇和丙硫基这两处,为什么让强制降解的产物归属格外难做The Degradation Profile of Ticagrelor: Why Cyclopentanediol and the Propylthio Group Make Degradant Assignment Unusually Hard
替格瑞洛自带多个敏感位点,亲水又难保留。本文从结构出发拆解它的降解方向、强制降解试验的设计难点,以及降解杂质与工艺杂质在申报时的归属边界。Ticagrelor carries several sensitive sites and is both hydrophilic and poorly retained. From the structure, this article unpacks its degradation…
2026-10-13

品种杂质谱Impurity Profile

品种杂质谱Impurity Profile
Aspirin's 0.10 Percent Is Four Different Numbers, and Its Impurities Grow by One Acetyl at a Time
From 75 mg to 4 g a day, aspirin's impurity thresholds change meaning; salicylic acid and its ester cascade explain the rest of the file
2026-11-16
品种杂质谱Impurity Profile
Rifampicin Hydrolyses Into Two Halves, and the Balance Closes at 115.18
Rifampicin is a hydrazone holding an 823 Da molecule together. Its mass balance, its quinone, and why isoniazid in the same tablet accelerates the loss.Rifampicin is a hydrazone holding an 823 Da molecule together. Its mass balance, its quinone, and why isoniazid in the same tablet accelerates the…
2026-11-14
品种杂质谱Impurity Profile
Captopril: Ten Lettered Impurities, One Route, and a Disulfide With Two Origins
Most captopril EP impurities are route intermediates, not degradants. EP J at 259.32 minus 42.04 is the drug, and the disulfide is the only aqueous degradant.Most captopril EP impurities are route intermediates, not degradants. EP J at 259.32 minus 42.04 is the drug, and the disulfide is the only aqueous…
2026-11-13
品种杂质谱Impurity Profile
Ambroxol: One Secondary Amine, Four Impurities, and No Way to Design the Amine Out
Ambroxol's only secondary amine is the pharmacophore, the nitrosation site and the ring-closure site, so its impurity map is structural rather than process-drivenAmbroxol's only secondary amine is the pharmacophore, the nitrosation site and the ring-closure site, so its impurity map is structural rather than…
2026-11-12
品种杂质谱Impurity Profile
Clindamycin Hydrochloride: An Acetonide, a 7-Epimer, and a Palmitate That Is Not an Impurity of This Salt
Clindamycin has one synthetic step: chlorine for the C7 hydroxyl. Almost every impurity traces to that carbon, the fermenter, or an ester of another product.Clindamycin has one synthetic step: chlorine for the C7 hydroxyl. Almost every impurity traces to that carbon, the fermenter, or an ester of another…
2026-11-11
品种杂质谱Impurity Profile
Lisinopril Closes a Ring It Was Not Supposed to Close, and It Does So Twice
Lisinopril has no ester, yet it cyclises to a diketopiperazine. The catalogue holds two of them, differing only at the proline ring junction, and most files carry one.Lisinopril has no ester, yet it cyclises to a diketopiperazine. The catalogue holds two of them, differing only at the proline ring junction, and…
2026-11-10
品种杂质谱Impurity Profile
Ezetimibe: The Main Degradant Is an Isomer of the Drug
Ezetimibe's azetidinone ring rearranges into a tetrahydropyran of identical mass, and the drug dimerises inside glass vials. Both reshape method design.Ezetimibe's azetidinone ring rearranges into a tetrahydropyran of identical mass, and the drug dimerises inside glass vials. Both reshape method…
2026-11-09
品种杂质谱Impurity Profile
Furosemide: The Starting Material Is Also the Degradant, So Release Testing Proves Nothing
One benzylic C-N bond carries the whole impurity story. Acid and light both cut it, and the fragment left behind is the same anthranilic acid the route starts from.One benzylic C-N bond carries the whole impurity story. Acid and light both cut it, and the fragment left behind is the same anthranilic acid the…
2026-11-06
品种杂质谱Impurity Profile
Pregabalin: The Impurity Profile of a Molecule That Reacts With Itself
One carboxylic acid at one end, one primary amine at the other. The lactam is only the first product; the same pair of groups also builds a ten-membered cyclic dimer and reacts with lactose.One carboxylic acid at one end, one primary amine at the other. The lactam is only the first product; the same pair of groups also builds a…
2026-11-05
品种杂质谱Impurity Profile
Ceftriaxone Sodium: Five Impurities, Five Origins, and the One That Grows in the Light
An E/Z isomer, a triazine fragment, an activated thioester and a hydrazine-type residue share one impurity list. Each has a different origin and a different control point.An E/Z isomer, a triazine fragment, an activated thioester and a hydrazine-type residue share one impurity list. Each has a different origin and a…
2026-11-04
品种杂质谱Impurity Profile
碘海醇的杂质主线不是亚硝胺,而是侧链 O-烷基化:一个反应给出三个位置异构体Iohexol's Main Impurity Line Is Not Nitrosamine but Side-Chain O-Alkylation: One Reaction, Three Regioisomers
碘海醇的杂质难点集中在侧链仲羟基的 O-烷基化:同一三碘母核可给出多个位置异构体,高分辨质谱无法区分。本文从合成化学、环氧化物中间体去向、色谱定位、同族横向对比与申报发补五个角度拆解,并附本目录 33 张产品卡的同分子式分组。Iohexol's impurity difficulty centres on O-alkylation of the secondary hydroxyls on the side chain: the same triiodo nucleus can give several…
2026-11-02
品种杂质谱Impurity Profile
哌拉西林钠:2,3-二氧哌嗪侧链,既是聚合杂质的成核点,也是第二个过敏原Piperacillin Sodium: The 2,3-Dioxopiperazine Side Chain Is Both the Nucleus for Polymeric Impurities and a Second Allergen
哌拉西林的麻烦不在 β-内酰胺环,而在侧链那个带两个氮的 2,3-二氧哌嗪。它既是聚合杂质的成核点,又是白蛋白上第二个 hapten(535 amu)的来源。本文从结构、降解、加合化学、亚硝胺判定与申报五个角度把这个品种讲透。Piperacillin's trouble is not the β-lactam ring but the 2,3-dioxopiperazine on the side chain with its two nitrogens. It is both the nucleation point…
2026-11-02
品种杂质谱Impurity Profile
磷酸奥司他韦的降解产物里,有它自己的活性代谢物:两条水解轴、一对同分子式异构体,和柠檬酸挖的坑Among Oseltamivir Phosphate's Degradants Is Its Own Active Metabolite: Two Hydrolysis Axes, a Pair of Same-Formula Isomers, and a Trap Set by Citric Acid
按 ICH Q1A 做强制降解,这个品种只给出五个降解物,看起来干净。但这五个产物分属两条独立的水解轴,还夹着两对同分子式的位置异构体;其中最主要的那个酸,结构上正是它的活性代谢物。真正容易被漏掉的,是商品干混悬剂里与枸橼酸缩合出来的两个酰胺。Forced degradation per ICH Q1A gives only five degradants for this substance, which looks clean. But they belong to two independent hydrolysis axes…
2026-10-31
品种杂质谱Impurity Profile
利伐沙班的三个羰基:碱里一小时、酸里一整天的降解速率差从哪来Rivaroxaban's Three Carbonyls: Where the One-Hour-in-Base Versus One-Day-in-Acid Rate Difference Comes From
利伐沙班做强制降解,最容易写出的结论是「酸碱都不稳定」。这句话不错,但没有信息量。它的分子上挂着三个可水解的羰基,还有一处 C–Cl、一个手性中心,几条通道的触发条件差得很远:同一当量浓度下,碱里 1 小时就能到 5%,酸里要泡 24 小时。The easiest conclusion from rivaroxaban forced degradation is that it is unstable in both acid and base. True, but uninformative: three hydrolysable…
2026-10-30
品种杂质谱Impurity Profile
他克莫司为什么总在硬脂酸镁那里翻车:一个由二价金属催成的重排Why Tacrolimus Keeps Failing at Magnesium Stearate: A Rearrangement Catalysed by a Divalent Metal
他克莫司的强制降解里有四条通道,但制剂里涨得最快的那一个杂质既不是水解也不是氧化,而是硬脂酸镁促成的 benzilic 酸型重排,产物是一个 α-羟基酸。这篇文章把四条通道分开、把重排讲透,并说明为什么同分子式的十条目靠质谱分不开。Tacrolimus forced degradation shows four channels, but the impurity that grows fastest in the formulation is neither hydrolysis nor oxidation: it is…
2026-10-29
品种杂质谱Impurity Profile
紫杉醇的 C7 差向化:EP 杂质 E 是唯一会在溶液里自己长出来的那一个C7 Epimerisation of Paclitaxel: EP Impurity E Is the One That Grows by Itself in Solution
紫杉醇的十八条 EP 字母杂质看起来是一张平铺的清单,其实分属三张完全不同的来源表:红豆杉共萃、半合成保护基残留、以及贮存中自己长出来的降解物。7-表紫杉醇(EP 杂质 E)属于第三类,它的生成不需要任何外来试剂,生理条件就够了——这决定了它该进稳定性而不是进起始物料标准。Paclitaxel's eighteen EP letter impurities look like a flat list but belong to three entirely different source tables: co-extraction from yew…
2026-10-28
品种杂质谱Impurity Profile
头孢呋辛酯的 50:50 不是纯度问题:两个酯键、两个非对映体,和一场发生在溶出杯里的水解Cefuroxime Axetil's 50:50 Is Not a Purity Problem: Two Ester Bonds, Two Diastereomers, and a Hydrolysis That Happens in the Dissolution Vessel
头孢呋辛酯是前药酯,分子里有两个性质完全不同的酯键,C4 上那个 1-乙酰氧基乙酯还额外造出一个手性中心,使原料药本身就是 A、B 两个非对映体的 50:50 混合物。它的主要降解物是头孢呋辛、Δ2 异构体与 α/β-亚砜,而水解速率会被乙酸盐与磷酸盐缓冲液催化——这直接影响溶出介质怎么选、曲线怎么做、BE 怎么解释。Cefuroxime axetil is a prodrug ester with two ester bonds of very different character, and the 1-acetoxyethyl ester at C4 creates an additional…
2026-10-27
品种杂质谱Impurity Profile
盐酸莫西沙星的降解杂质谱:一条被甲氧基堵死的通道,两条 HPLC 看不见的通道The Degradation Profile of Moxifloxacin Hydrochloride: One Channel Blocked by a Methoxy Group and Two Channels HPLC Cannot See
莫西沙星常被当成「光稳定性最好的喹诺酮」,于是强制降解照抄四件套。但它的 C8 甲氧基把一条光解主路封死了,而真正容易漏掉的是两类 HPLC-UV 根本看不见的东西:不带发色团的环丙胺,和双环二胺上的立体异构体。本文按结构位点拆它的降解谱,并把方法学上的盲区标出来。Moxifloxacin is often treated as the most photostable quinolone, so forced degradation copies the standard four conditions. But its C8 methoxy group…
2026-10-26
品种杂质谱Impurity Profile
磷酸西格列汀的降解杂质谱:一个三唑并哌嗪片段,怎么从水解物变成 37 ng/天 的 NTTPThe Degradation Profile of Sitagliptin Phosphate: How a Triazolopiperazine Fragment Becomes a 37 ng/day NTTP
磷酸西格列汀的 191 条杂质条目里,真正决定降解研究路线的是一个只有 6 个碳的片段 TTP。它既是酰胺水解的必然产物,也是工艺带入的起始物料残留,还能在片剂里被辅料亚硝酸盐咬一口,变成可接受摄入量仅 37 ng/天 的 NTTP。本文用分子式差把片剂降解物分组,并说明同分子式条目成组出现时方法怎么搭。Among the 191 impurity entries for sitagliptin phosphate, the one that actually determines the degradation strategy is a six-carbon fragment, TTP. It…
2026-10-25
品种杂质谱Impurity Profile
利奈唑胺的 3-氟-4-吗啉基苯胺:一个起始物料片段,为什么在注射液里越放越多Linezolid's 3-Fluoro-4-Morpholinoaniline: Why a Starting-Material Fragment Grows During Storage of the Injection
利奈唑胺有 108 条杂质条目,真正需要单独盯的是那条芳香胺:3-氟-4-吗啉基苯胺。它既是合成路线必经的苯胺中间体,又能在注射液的水相与溶解氧里由母体降解生成——83 批抽验全部检出,加速试验中含量还会上升,而配液灌装充氮能把溶解氧压到 2 ppm 以下使它明显下降。本文拆三条来源线、按 TTC 折算出的 1.25 ppm 控制线、以及芳香胺为什么不能按结构类推限值。Linezolid has 108 impurity entries, but the one needing separate attention is the aromatic amine 3-fluoro-4-morpholinoaniline. It is both an…
2026-10-24
品种杂质谱Impurity Profile
阿莫西林的聚合物杂质:为什么药典拿青霉素当对照品,还要乘 0.1Amoxicillin Polymer Impurities: Why the Pharmacopoeia Uses Penicillin as Reference Standard and Still Multiplies by 0.1
阿莫西林的侧链带一个游离 α-氨基,这让它比苄青霉素多出两条分子间聚合路径,也让「聚合物」在中国药典里必须单列一项、用葡聚糖凝胶 G-10 而不是 C18 来测。本文讲清三件事:聚合物为什么是 2 到 n 聚的同系物而非单一杂质、为什么对照品用青霉素并乘 0.1 的校正因子、以及 EP/USP 走的是另一条「具体寡聚体」的路。附 G-10 方法的关键参数与系统适用性判据。Amoxicillin's side chain carries a free α-amino group, giving it two intermolecular polymerisation pathways that benzylpenicillin lacks and forcing…
2026-10-23
品种杂质谱Impurity Profile
奥美沙坦酯的降解:当主降解产物就是活性成分,限度该怎么定Degradation of Olmesartan Medoxomil: When the Main Degradant Is the Active Ingredient, How Should the Limit Be Set?
奥美沙坦酯是酯前药,它的主降解产物就是活性代谢物奥美沙坦,EP 把它编为杂质 A。本文用分子式算出脱落的 medoxomil 片段,说明为什么它的限度逻辑不能照抄未知降解物,并给出碱档强降解的可归属窗口、质量平衡三个漏点、N3 区域异构体这条被低估的通道,以及制剂端水分与碱性辅料的处理。Olmesartan medoxomil is an ester prodrug whose main degradant is the active metabolite olmesartan, designated EP Impurity A. This article calculates…
2026-10-20
品种杂质谱Impurity Profile
瑞舒伐他汀钙的降解杂质谱:内酯化是可逆平衡,不是单向降解The Degradation Profile of Rosuvastatin Calcium: Lactonisation Is a Reversible Equilibrium, Not One-Way Degradation
瑞舒伐他汀钙的侧链上,内酯化、3-位氧化、N-去甲基、E/Z 异构四条通道互相牵制,还会两两叠加成「N-去甲基内酯」这类组合杂质。本文拆解每个位点的成因、强制降解怎么设计才不被平衡误导、钙盐折算与「单体/盐」对照品的坑,并与辛伐他汀、阿托伐他汀钙、匹伐他汀钙逐条对比哪些结论不能照搬。On rosuvastatin calcium's side chain, lactonisation, 3-position oxidation, N-demethylation and E/Z isomerisation constrain one another and combine…
2026-10-19
品种杂质谱Impurity Profile
苯磺酸氨氯地平的降解杂质谱:二氢吡啶环的光致芳构化,为什么不靠氧气也会发生The Degradation Profile of Amlodipine Besylate: Why Photo-Aromatisation of the Dihydropyridine Ring Proceeds Without Oxygen
苯磺酸氨氯地平是 1,4-二氢吡啶类降压药中用量最大的品种之一。它的光解路径有一个反直觉之处:把二氢吡啶环氧化成吡啶环这一步并不需要氧气参与,所以充氮保护替代不了避光。本文拆解这个品种的三条降解通道、强制降解设计与申报口径。Amlodipine besylate is one of the most widely used 1,4-dihydropyridine antihypertensives. Its photolysis has a counter-intuitive feature: oxidising…
2026-10-18
品种杂质谱Impurity Profile
阿哌沙班的降解杂质谱:三个羰基,三条完全不同的水解通道The Degradation Profile of Apixaban: Three Carbonyls, Three Entirely Different Hydrolysis Channels
阿哌沙班分子上有两个内酰胺和一个伯酰胺,看起来「都是酰胺,一起水解」,实际三条通道的速率差一个量级。本文按羰基逐个拆解强制降解设计、pH 无关水解通道的含义、O-去甲基与代谢物条目的区分、10 个有关物质一法覆盖的取舍,以及酸碱双敏品种最容易做出来的过度破坏。Apixaban carries two lactams and a primary amide, which look like all amides hydrolysing together, yet the three channels differ in rate by an order…
2026-10-17
品种杂质谱Impurity Profile
乙酰半胱氨酸的降解杂质谱:一个游离巯基,把样品处理、方法开发和稳定性设计全改写了The Degradation Profile of Acetylcysteine: One Free Thiol That Rewrites Sample Handling, Method Development and Stability Design
从乙酰半胱氨酸的巯基-酰胺-羧基三个官能团出发,拆解它的氧化与脱乙酰两条降解通道、药典杂质命名与降解链的对应关系、与甘露醇等辅料的加合物风险,以及含巯基药物在方法开发与强制降解设计上的实操要点。Starting from acetylcysteine's thiol, amide and carboxyl groups, this article covers its two degradation channels of oxidation and deacetylation, the…
2026-10-16
品种杂质谱Impurity Profile
阿哌沙班的基因毒性杂质:从合成路线推导到控制策略Genotoxic Impurities in Apixaban: From Synthetic Route to Control Strategy
阿哌沙班的警示结构不在母体,而在带游离氨基的中间体与亚硝胺衍生物上。本文从公开合成路线出发,梳理 ICH M7 的评估路径、分析方法选择、以及 EMA 审评中真实被追问的问题。Apixaban's structural alerts are not in the parent but in amino-bearing intermediates and nitrosamine derivatives. Starting from published synthetic…
2026-10-12
品种杂质谱Impurity Profile
替尼类激酶抑制剂的基因毒性杂质:警示结构从哪来、怎么系统排查Genotoxic Impurities in Tinib Kinase Inhibitors: Where Structural Alerts Come From and How to Screen Systematically
替尼类是基因毒性杂质的高发区,原因不在药理分类而在合成化学:多步偶联、芳香胺中间体、含氮杂环密集。本文拆解警示结构的三个来源,并给出按路线逐步扫描的落地方法。Tinibs are a hotspot for genotoxic impurities, not because of their pharmacology but because of synthetic chemistry: multi-step couplings, aromatic…
2026-10-12
品种杂质谱Impurity Profile
沙坦类药物的亚硝胺杂质:从缬沙坦事件倒推工艺风险点Nitrosamine Impurities in Sartans: Working Back From the Valsartan Event to Process Risk Points
从 2018 年缬沙坦 NDMA 事件的根因链条出发,拆解四氮唑成环步骤里「溶剂 + 淬灭剂」的组合风险,并说明仿制药应当把亚硝胺控制前移到路线设计阶段的理由与方法。Starting from the causal chain of the 2018 valsartan NDMA event, this article unpacks the combined solvent-and-quench risk in the tetrazole…
2026-10-11

药典差异Pharmacopoeial Differences

药典差异Pharmacopoeial Differences
左甲状腺素钠的 2.0% 与 0.15%:一个微克级品种的杂质限度为什么宽出一个量级Levothyroxine Sodium's 2.0% and 0.15%: Why a Microgram-Dose Substance Has Impurity Limits an Order of Magnitude Wider
同一个分子,ICH 说到 0.15% 就该界定,USP 却允许碘塞罗宁放到 2.0%。这个差不是药典放水,而是「活性同系物 + 微克级剂量 + 化学上压不下去」三件事叠出来的结果。更麻烦的是,真正让片剂效价掉下去的往往不是化学降解,而是五水合物脱水、歧化——而 HPLC 恰恰看不见这一步。For the same molecule ICH says qualification starts at 0.15% while USP allows liothyronine up to 2.0%. The gap is not pharmacopoeial slack but the…
2026-10-28
药典差异Pharmacopoeial Differences
盐酸万古霉素的有关物质:一半来自菌种,一半来自水解,而两套命名体系对不上Related Substances of Vancomycin Hydrochloride: Half From the Organism, Half From Hydrolysis, and the Two Naming Systems Do Not Match
万古霉素是发酵来的三联糖肽,它的「杂质」里大部分不是合成副产物,而是发酵过程中一起长出来的同系物——差一个甲基、少一个氯、缺一个糖。真正由水解产生的只有一个:CDP-1,也就是 EP 杂质 B。这篇文章讲清这两类杂质的不同控制逻辑,以及 EP 字母、USP 相关化合物、相对保留时间三套口径为什么很难一一对齐,顺带算一笔 2 g/日 剂量下阈值被绝对量反压的账。Vancomycin is a fermentation-derived tricyclic glycopeptide whose impurities are mostly congeners grown alongside it, differing by a methyl, a…
2026-10-27
药典差异Pharmacopoeial Differences
地塞米松的 16-差向异构体:RRT 只差 0.06,中美的限度差了 3 倍Dexamethasone's 16-Epimer: An RRT Difference of Only 0.06 and a Threefold Limit Gap Between Two Pharmacopoeias
地塞米松最难缠的杂质是倍他米松——16 位甲基翻个面就是另一个上市药,分子式完全相同。这决定了它的限度不能按毒理推导:日剂量只有几毫克,ICH Q3A 的 1.0 mg/日 天花板根本用不上。本文拆解三件事:为什么这个杂质更像路线带入而不是贮存降解、RRT 0.94 与 1.00 之间的分离窗口有多窄、以及中国药典 0.5% 与 USP 0.15% 这 3 倍差距背后的两套算法(含 USP 给 7,9-二烯的 1.7 响应因子会让结果差 70%)。Dexamethasone's most troublesome impurity is betamethasone, another marketed drug produced by flipping the 16-methyl group, with an identical…
2026-10-23
药典差异Pharmacopoeial Differences
瑞舒伐他汀钙的杂质控制:EP 的字母编号、USP 与药典各管哪一段,盐型条目最容易踩错Impurity Control for Rosuvastatin Calcium: EP Letters, USP and Pharmacopoeial Scope, and Where Salt-Form Entries Go Wrong
瑞舒伐他汀钙的杂质研究里,真正的坑不在化学,而在「同一个杂质的三种条目形式」与三套药典体系的编号习惯。本文从杂质族结构成因讲起,再到盐型条目选择与限度推导。The real trap in rosuvastatin calcium impurity work is not chemistry but the three entry forms of the same impurity and the numbering habits of three…
2026-10-13
药典差异Pharmacopoeial Differences
同一母体不同盐型:杂质命名与编号体系差在哪(阿托伐他汀 / 氨氯地平 / 氯吡格雷实证)One Parent, Different Salts: How Impurity Naming and Numbering Diverge, With Evidence From Atorvastatin, Amlodipine and Clopidogrel
以目录中 99 组「同母体多形式」品种为样本,用九组真实对照说明盐型与游离碱的编号杂质条目交集有多小、药典字母映射如何在盐型上叠加,以及申报与采购时最容易混淆的三个点。Using 99 one-parent-multiple-forms groups in the catalogue as a sample and nine real comparisons, this article shows how little the numbered impurity…
2026-10-12
药典差异Pharmacopoeial Differences
EP、USP 与中国药典的杂质对照品体系差异:同一个杂质,为什么三家的“身份”不一样How the Impurity Reference Standard Systems of EP, USP and ChP Differ: Why One Impurity Has Three Different Identities
对比欧洲药典(EP)、美国药典(USP)与中国药典(ChP)在杂质命名、对照品体系、法定地位与替代规则上的差异,并给出跨体系品种的对照品选用与申报实操建议。A comparison of the European, United States and Chinese Pharmacopoeias in impurity naming, reference standard systems, legal standing and…
2026-10-10

行业观察Industry Insight

行业观察Industry Insight
达比加群酯胶囊的逆向工程:胃 pH 升到 5.3,暴露量掉七成,那粒酒石酸到底在干什么Reverse Engineering Dabigatran Etexilate Capsules: Gastric pH Rises to 5.3, Exposure Falls by Seventy Percent, So What Is That Tartaric Acid Doing?
达比加群酯是双前药,绝对生物利用度只有 3–7%。原研胶囊的内容物不是普通颗粒,而是「酒石酸丸芯+药物层」的微丸。日本一项对照研究显示:简化成普通片剂后标准条件下对胶囊生物等效,但受试者先用雷贝拉唑把胃内 pH 抬到 5.3,AUC 就从 667 掉到 192 ng·h/mL。本文讲这颗胶囊逆向工程该测什么、辅料表为什么抄不出处方、酸在稳定性与亚硝胺上扮演的双重角色,以及 BE 与发补的三个必答项。Dabigatran etexilate is a double prodrug with absolute bioavailability of only 3–7%. The originator capsule is not ordinary granules but pellets…
2026-10-22
行业观察Industry Insight
盐酸雷尼替丁的 NDMA:为什么它不在杂质谱里,却让整个品种退市NDMA in Ranitidine Hydrochloride: Why It Is Absent From the Impurity Profile Yet Took the Whole Substance Off the Market
本目录收录盐酸雷尼替丁 33 条、含 9 个 EP 字母杂质,却没有一条是 NDMA。本文解释这个「缺项」背后的化学:沙坦类是母体骨架被亚硝化的 NDSRI,雷尼替丁是 Mannich 碱裂解后释放二甲胺再生成 NDMA,两者控制逻辑完全不同。附监管时间线、300 mg/天 下 0.32 ppm 的折算过程,以及工艺、辅料、包装三道闸门。This catalogue holds 33 ranitidine hydrochloride entries including nine EP letter impurities, and none of them is NDMA. This article explains the…
2026-10-20

对照品实务Reference Standard Practice

对照品实务Reference Standard Practice
Levofloxacin Impurity A at Fifty Per Cent Is Ofloxacin: Choosing a Standard for a Chiral Boundary
EP impurity A is the enantiomer that is half of ofloxacin, five catalog entries share the API formula, and the hemihydrate moves every reported percentage by 2.4 per centEP impurity A is the enantiomer that is half of ofloxacin, five catalog entries share the API formula, and the hemihydrate moves every reported…
2026-11-17
对照品实务Reference Standard Practice
利伐沙班的杂质对照品:EP 字母、目录编号与成盐形态,三套叫法怎么对上Reference Standards for Rivaroxaban: How EP Letters, Catalogue Numbers and Salt Forms Line Up
利伐沙班有 193 个编号杂质,但 EP 字母只标到 9 个,而且 A 是对映体、E 是去氯物、H 是二氯物——字母不是序号,编号也不是顺序。本文把 EP 字母、目录编号、CAS 与成盐形态四套标识打通,讲清「单体/盐酸盐」两种形态的配液差别、纯度与含量为什么不等于一回事、去氯物的校正因子为什么不能默认 1.0,以及 5 条 N-亚硝基条目为什么全挂在「杂质 X」上。Rivaroxaban has 193 numbered impurities but only nine EP letters, and A is the enantiomer, E the deschloro compound and H the dichloro compound…
2026-10-19
对照品实务Reference Standard Practice
有药典收载 vs 无药典收载:杂质对照品选用与方法学策略的技术差异Pharmacopoeially Monographed Versus Not: Technical Differences in Reference Standard Selection and Method Strategy
同样是仿制药,为什么有的项目能直接对标药典方法,有的必须从零自建?本文把「收载」与「未收载」两种情形在方法来源、对照品法定性、标定深度与申报表述上的差异逐项讲清楚。Why can some generic projects work directly against a pharmacopoeial method while others must build from zero? This article sets out the differences…
2026-10-12
对照品实务Reference Standard Practice
供应商目录编号 ≠ 药典编号:申报中最常见的混淆点与对照方法Supplier Catalogue Numbers Are Not Pharmacopoeial Numbers: The Most Common Confusion at Filing and How to Reconcile Them
供应商目录里的「杂质 3」和药典专论里的「Impurity C」是两套完全独立的编号体系。这篇文章用我们自建目录的真实条目做对照实例,说明两套编号的来源、混淆会造成的三类后果,并给出可直接照做的四列对照表与采购核对清单。Impurity 3 in a supplier catalogue and Impurity C in a pharmacopoeial monograph are two entirely independent numbering systems. Using real entries…
2026-10-11
对照品实务Reference Standard Practice
大杂质系列品种的对照品体系:300+ 条杂质从哪来、仿制药该怎么买Reference Standard Systems for Substances With Large Impurity Series: Where 300-Plus Impurities Come From and How Generics Should Buy Them
以塞普替尼(316 条)、乙酰半胱氨酸(272 个编号杂质但编号触 382)等大杂质系列品种为例,拆解一个现代 API 杂质对照品体系的来源构成,并给出分期采购与优先级建议。Using large impurity-series substances such as selpercatinib (316 entries) and acetylcysteine (272 numbered impurities although numbering reaches…
2026-10-11

发补实务Deficiency Practice

发补实务Deficiency Practice
Tamsulosin at 0.4 mg: Generous Limits, and a Method That Still Fails
At 0.4 mg a day the mutagenicity threshold works out to thousands of ppm. The deficiency questions concern purging the alkyl bromide and resolving the enantiomer.At 0.4 mg a day the mutagenicity threshold works out to thousands of ppm. The deficiency questions concern purging the alkyl bromide and resolving…
2026-11-09
发补实务Deficiency Practice
恩替卡韦的发补:三个手性中心,为什么不能塞进一张有关物质图谱Entecavir Deficiency Responses: Three Stereocentres That Will Not Fit on One Related-Substances Chromatogram
0.5 mg 的日剂量让所有杂质阈值都退化成纯百分比,0.10% 只对应 0.5 μg;三个手性中心理论上给出七种立体异构体,一张 C18 图谱分不开;而真正容易被忽略的是糖苷键水解出来的鸟嘌呤——极性太大,在反相柱上几乎不保留。三件事叠起来,就是恩替卡韦发补的固定剧本。A 0.5 mg daily dose collapses every impurity threshold into a pure percentage, where 0.10 percent corresponds to only 0.5 micrograms. Three…
2026-11-03

全部文章All articles